Misplaced Pages

Jerome Sarris

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Australian academic

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2019)

Jerome Sarris is Co-CEO of Psychae Therapeutics and Co-Director of the associated Not-For-Profit Psychae Institute. He was appointed Professor of Psychedelic Medicine at The Centre of Mental Health at Swinburne University of Technology He also holds Adjunct roles at NICM Health Research Institute at Western Sydney University, Australia, and at the Florey Institute of Neuroscience and Mental Health at the University of Melbourne, Australia.

Sarris' principal research interests pertain to the development and clinical study of psychedelic therapies and psychoactive plant-based medicines for mental disorders and other diseases. He is also interested in lifestyle medicine in anxiety and mood disorders, psychotropic plant medicines (such as kava), as well as the use of pharmacogenetics to guide psychiatric treatment. He is involved in prominent research projects investigating the therapeutic potential of psychedelic medicines.

Early life

Jerome Sarris was born in Sydney, Australia. He was raised on the North Shore of Sydney and attended Mosman Preparatory School. After moving to Brisbane at age 9, Sarris attended Ironside State School, then Brisbane Boys College. At age 17, Sarris lived in Glastonbury, England, for several years before returning to Brisbane to pursue further study. Sarris' heritage is primarily Austrian, German and French, and he has a great-grandmother from the Polynesian Gilbertese Islands.

Academic career

Sarris has completed a Doctorate in the field of Psychiatry at the University of Queensland under the mentorship of Professors David Kavanagh and Gerard Byrne. Sarris has also completed advanced diplomas and degrees in the health science field, including plant medicine (specialising in psychoactives), naturopathy (including the study of clinical medicine), acupuncture and nutrition, and has practiced clinically in these areas. During this period of clinical practice, Sarris obtained a Master's degree majoring in plant-based medicine under Kerry Bone at the University of New England, Australia. After receiving a National Health and Medical Research Council (NHMRC) Early Career Fellowship he undertook his postdoctoral training at the University of Melbourne, under the mentorship of Professor Isaac Schweitzer, and has undertaken study in the field of Psychology. His post-doctoral studies were also based at The Centre of Human Psychopharmacology at Swinburne University of Technology with Con Stough and Andrew Scholey, as well as The Depression Clinical Research program at Harvard Medical School with David Mischoulon. Sarris held the role of Deputy and Research Director at NICM Health Research Institute before transitioning to Biotech entrepreneurial work at Psychae Therapeutics (co-seeded by Genesis and Tin Alley Ventures funds; based at Melbourne University).

Research and scientific contributions

Sarris is currently involved in prominent research projects investigating the therapeutic use of psychedelic medicines (including Psilocybin and Ayahuasca) and medical cannabis. He is a principal investigator on the Global Ayahuasca Project, has published several research studies investigating the use of psychedelic medicines in psychiatric conditions, and is a founding member of the Medicinal Psychedelics Research Network at the University of Melbourne. Sarris is Chair of the Integrative and Complementary Medicine Task Force of the World Federation of Societies of Biological Psychiatry.

Previously, Sarris' main research contributions have been in the areas of integrative mental health, nutritional psychiatry and in the development of evidence-based practice in naturopathy. He has co-authored a textbook, and published many highly cited papers in these fields. His work has impacted treatment guidelines for mood and anxiety disorders. Sarris has advocated for a more integrated model of treatment of depression, involving an evidence-based application of select nutraceuticals and lifestyle modification, alongside mainstream judicious use of pharmacotherapies and psychological techniques. Sarris has been a prominent figure in the investigation of South Pacific psychotropic medicinal plant kava (Piper methysticum), playing an assistance role in the direction of kava policy at the Australian Therapeutic Goods Administration. He has conducted several RCTs in anxiety and mood disorder involving extracts of this plant. His research on traditional water-extracted noble cultivars of the plant has influenced the safety guidelines around usage and development of such extracts for the treatment of anxiety. Sarris was on the executive committee of The International Network of Integrative Mental Health, The International Society for Nutritional Psychiatry Research, and the Australian Medicinal Cannabis Research and Education Collaboration (co-founded with Justin Sinclair).

References

  1. ^ "Our Team — Psychae Institute | Psychedelic Research Global Network". Psychae Institute. Retrieved 11 June 2024.
  2. Booker, Chloe (29 July 2021). "$40m psychedelic medicine institute launches in Melbourne". The Sydney Morning Herald. Retrieved 11 June 2024.
  3. "Profiles". www.westernsydney.edu.au. Retrieved 11 June 2024.
  4. findanexpert.unimelb.edu.au https://findanexpert.unimelb.edu.au/profile/343780-jerome-sarris. Retrieved 11 June 2024. {{cite web}}: Missing or empty |title= (help)
  5. "Jerome Sarris". The Conversation. 13 May 2013. Retrieved 11 June 2024.
  6. ^ "Global Ayahuasca Project". Global Ayahuasca Project. Retrieved 11 June 2024.
  7. ^ Abud-Rouch, Aaron (24 September 2019). "Medicinal Psychedelics Research Network (MPRN)". Faculty of Arts. Retrieved 11 June 2024.
  8. "Jerome Sarris LinkedIn".
  9. "NICM HRI | Jerome Sarris". www.nicm.edu.au. Retrieved 11 June 2024.
  10. "Publications — Psychae Institute | Psychedelic Research Global Network". Psychae Institute. Retrieved 11 June 2024.
  11. "Task Forces | WFSBP". Retrieved 11 June 2024.
  12. Sarris, Jerome. Clinical Naturopathy: An evidence-based guide to practice (2019 ed.). Elsevier Health Sciences.
  13. Ravindran, Arun V.; Balneaves, Lynda G.; Faulkner, Guy; Ortiz, Abigail; McIntosh, Diane; Morehouse, Rachel L.; Ravindran, Lakshmi; Yatham, Lakshmi N.; Kennedy, Sidney H.; Lam, Raymond W.; MacQueen, Glenda M.; Milev, Roumen V.; Parikh, Sagar V.; the CANMAT Depression Work Group (September 2016). "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments". The Canadian Journal of Psychiatry. 61 (9): 576–587. doi:10.1177/0706743716660290. ISSN 0706-7437. PMC 4994794. PMID 27486153.
  14. Sarris, Jerome; Logan, Alan C; Akbaraly, Tasnime N; Amminger, G Paul; Balanzá-Martínez, Vicent; Freeman, Marlene P; Hibbeln, Joseph; Matsuoka, Yutaka; Mischoulon, David; Mizoue, Tetsuya; Nanri, Akiko; Nishi, Daisuke; Ramsey, Drew; Rucklidge, Julia J; Sanchez-Villegas, Almudena (March 2015). "Nutritional medicine as mainstream in psychiatry". The Lancet Psychiatry. 2 (3): 271–274. doi:10.1016/s2215-0366(14)00051-0. ISSN 2215-0366. PMID 26359904.
  15. "World first clinical trial supports use of Kava to treat anxiety". ScienceDaily. Retrieved 11 June 2024.
  16. Mitchell, Kristin; Contributor, WebMD Editorial. "All About Anxiety Disorders: From Causes to Treatment and Prevention". WebMD. Retrieved 11 June 2024. {{cite web}}: |last2= has generic name (help)
  17. Sarris, Jerome; Stough, Con; Bousman, Chad A.; Wahid, Zahra T.; Murray, Greg; Teschke, Rolf; Savage, Karen M.; Dowell, Ashley; Ng, Chee; Schweitzer, Isaac (October 2013). "Kava in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study". Journal of Clinical Psychopharmacology. 33 (5): 643–648. doi:10.1097/JCP.0b013e318291be67. ISSN 0271-0749. PMID 23635869.
  18. ^ Sarris, Jerome; Byrne, Gerard J; Bousman, Chad A; Cribb, Lachlan; Savage, Karen M; Holmes, Oliver; Murphy, Jenifer; Macdonald, Patricia; Short, Anika; Nazareth, Sonia; Jennings, Emma; Thomas, Stuart R; Ogden, Edward; Chamoli, Suneel; Scholey, Andrew (March 2020). "Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study". Australian & New Zealand Journal of Psychiatry. 54 (3): 288–297. doi:10.1177/0004867419891246. ISSN 0004-8674. PMID 31813230.
  19. Teschke, Rolf; Sarris, Jerome; Lebot, Vincent (15 January 2011). "Kava hepatotoxicity solution: A six-point plan for new kava standardization". Phytomedicine. 18 (2): 96–103. doi:10.1016/j.phymed.2010.10.002. ISSN 0944-7113. PMID 21112196.
  20. "AMCREC". Retrieved 11 June 2024.
Categories: